Finance

Lists
002727:SHE
Yixintang Pharmaceutical Co Ltd
CNÂĄ10.72
+0.75%
(+0.080) 1D
Sep 30, 3:04:09 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002727...
Open
CNÂĄ10.68
High
CNÂĄ10.77
Low
CNÂĄ10.62
Mkt. cap
6.28B
Avg. vol.
6.02M
Volume
4.81M
Dividend
3.73%
Quarterly dividend
CNÂĄ0.10
Ex-dividend date
Sep 24, 2026
P/E ratio
22.94
52-wk high
CNÂĄ14.80
52-wk low
CNÂĄ9.41
EPS
CNÂĄ0.47
Shares outstanding
585.60M
No. of employees
35K
Open
CNÂĄ10.68
High
CNÂĄ10.77
Low
CNÂĄ10.62
Mkt. cap
6.28B
Avg. vol.
6.02M
Volume
4.81M
Dividend
3.73%
Quarterly dividend
CNÂĄ0.10
Ex-dividend date
Sep 24, 2026
P/E ratio
22.94
52-wk high
CNÂĄ14.80
52-wk low
CNÂĄ9.41
EPS
CNÂĄ0.47
Shares outstanding
585.60M
No. of employees
35K
News stories
From web sources and news partners
About Yixintang Pharmaceutical Co Ltd
CEO-
Employees34.8K
FoundedNov 8, 2000
Headquarters-
SectorDrug
Websitehx8886.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.09B
4.34B
4.43B
4.03B
Cost of goods sold
2.70B
3.05B
2.97B
2.74B
Cost of revenue
2.70B
3.05B
2.97B
2.74B
Research and development expenses
1.30M
1.57M
797.19K
2.03M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.21B
1.25B
1.20B
1.21B
Operating expense
1.21B
1.30B
1.19B
1.21B
Total operating expenses
3.91B
4.35B
4.15B
3.95B
Operating income
174.68M
-14.76M
281.17M
85.87M
Other non operating income
-10.37M
7.40M
-543.11K
36.43K
EBT including unusual items
40.85M
43.99M
225.14M
121.49M
EBT excluding unusual items
135.97M
-37.76M
255.65M
65.14M
Income tax expense
19.51M
52.23M
47.31M
37.59M
Effective tax rate
47.75%
118.75%
21.01%
30.94%
Other operating expenses
-26.48M
23.96M
-16.25M
7.62M
Net income
18.94M
-5.16M
175.81M
81.04M
Net profit margin
0.46%
-0.12%
3.97%
2.01%
Earnings per share
0.01
-0.01
0.28
0.12
Interest and investment income
4.32M
3.69M
3.93M
5.46M
Interest expense
-32.65M
-34.10M
-28.91M
-26.23M
Net interest expenses
-28.34M
-30.40M
-24.98M
-20.77M
Depreciation and amortization charges
-
-
-
-
EBITDA
202.06M
12.28M
308.21M
111.26M
Gain or loss from assets sale
1.41M
-8.79M
-
-3.12M
AI content may include mistakes. Learn more
Google apps